Search research articles
Contact Us
Filters
Showing results (161-170 of 234) with videos related to
Page
of 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2011
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma
Marc Remke, Thomas Hielscher, Andrey Korshunov, et al.
Acta Neuropathologica
|
April 4, 2023
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification
Jack Goddard, Jemma Castle, Emily Southworth, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
August 5, 2021
Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial
Stefan Dietzsch, Annett Braesigk, Clemens Seidel, et al.
Neuro-Oncology
|
December 17, 2020
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study
Jonas E Adolph, Gudrun Fleischhack, Ruth Mikasch, et al.
Acta Neuropathologica
|
May 12, 2019
Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes
Tanvi Sharma, Edward C Schwalbe, Daniel Williamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 7, 2024
Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201
Jordan R Hansford, Gauthier Bouche, Vijay Ramaswamy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2012
Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial
Birgitta Lannering, Stefan Rutkowski, Francois Doz, et al.
Acta Neuropathologica
|
May 6, 2014
Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort
Torsten Pietsch, Rene Schmidt, Marc Remke, et al.
Acta Neuropathologica
|
December 2, 2022
Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts
Martin Mynarek, Denise Obrecht, Martin Sill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2019
Germline <i>GPR161</i> Mutations Predispose to Pediatric Medulloblastoma
Matthias Begemann, Sebastian M Waszak, Giles W Robinson, et al.
Page
of 24
Search research articles
Search
Showing results (161-170 of 234) with videos related to
Sort By:
Page
of 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2011
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma
Marc Remke, Thomas Hielscher, Andrey Korshunov, et al.
Acta Neuropathologica
|
April 4, 2023
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification
Jack Goddard, Jemma Castle, Emily Southworth, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
August 5, 2021
Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial
Stefan Dietzsch, Annett Braesigk, Clemens Seidel, et al.
Neuro-Oncology
|
December 17, 2020
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study
Jonas E Adolph, Gudrun Fleischhack, Ruth Mikasch, et al.
Acta Neuropathologica
|
May 12, 2019
Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes
Tanvi Sharma, Edward C Schwalbe, Daniel Williamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 7, 2024
Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201
Jordan R Hansford, Gauthier Bouche, Vijay Ramaswamy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2012
Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial
Birgitta Lannering, Stefan Rutkowski, Francois Doz, et al.
Acta Neuropathologica
|
May 6, 2014
Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort
Torsten Pietsch, Rene Schmidt, Marc Remke, et al.
Acta Neuropathologica
|
December 2, 2022
Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts
Martin Mynarek, Denise Obrecht, Martin Sill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2019
Germline <i>GPR161</i> Mutations Predispose to Pediatric Medulloblastoma
Matthias Begemann, Sebastian M Waszak, Giles W Robinson, et al.
Page
of 24